According to a recent LinkedIn post from Rillet, the company is highlighting new scheduling capabilities for its Aura Flow workflow tool aimed at finance teams. The post suggests users can design recurring processes once and have them automatically executed on a defined cadence to reduce manual effort and burnout.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
As described in the post, example use cases include weekly invoice pulls by subsidiary, monthly 13-week cash forecasts, weekly accounts receivable aging reports, monthly deferred revenue roll-forwards, and quarterly board-level financial summaries. These functions target core controllership and FP&A routines that are central to mid-sized and larger finance organizations.
For investors, the added scheduling functionality may strengthen Rillet’s value proposition as an automation layer for repeatable finance tasks, potentially deepening wallet share with existing customers. By embedding itself more tightly into recurring workflows, the platform could increase user stickiness and reduce churn, supporting more predictable subscription revenue.
The focus on forecasts, AR aging, and deferred revenue reporting also aligns Rillet with higher-value analytical and compliance activities rather than simple data retrieval. This positioning may allow the company to compete more directly with established finance automation and ERP-adjacent vendors, although the post does not provide information on pricing, customer adoption, or revenue impact.
The emphasis on time savings and reduced burnout reflects broader enterprise demand for tools that alleviate staffing constraints in finance teams. If Rillet can demonstrate measurable productivity gains on these recurring workflows, it could improve its competitive standing and support future growth, but the post offers no quantitative metrics or customer case studies to validate these potential benefits.

